Provided that the future is heading to precision medicine, the stratification of patients at risk of HCC, especially after treatment of HCV infection, will be mandatory. The evolving evidence shows that simple markers such as having FIB-4 scores > 3.25 or a general evaluation score > 6 points have an HCC incidence of > 3 % per year, well above the accepted minimum threshold [2], [3].

It is fair that the future recommendations will offer such a group of patients more frequent surveillance plans